目的全面收集国内外立体定向放射治疗(SBRT)和射频消融(RFA)治疗肝细胞癌(HCC)相关研究文献,通过Meta分析系统比较这两种治疗方法的临床效果及相关并发症。方法计算机检索PubMed、Embase、Cochrane Library、Scopus、Web of Science以...目的全面收集国内外立体定向放射治疗(SBRT)和射频消融(RFA)治疗肝细胞癌(HCC)相关研究文献,通过Meta分析系统比较这两种治疗方法的临床效果及相关并发症。方法计算机检索PubMed、Embase、Cochrane Library、Scopus、Web of Science以及中国生物医学文献(CBM)、知网、万方、维普等中英文数据库自建库至2022年6月发表的SBRT和RFA临床治疗HCC文献。采用Stata 14.0软件进行Meta分析。结果共纳入14项回顾性研究6806例患者。基于总生存期(OS)的综合风险比(HR)结果显示SBRT术后OS低于RFA术后(HR=1.25,95%CI=1.10~1.43,I^(2)=0%,P=0.0009),而局部控制(LC)比率的综合HR显示SBRT有更好的疗效(HR=0.61,95%CI=0.47~0.78,I^(2)=0%,P=0.0001)。亚组分析显示,LC比率的综合HR更支持对肿瘤直径>2 cm患者行SBRT(HR=2.64,95%CI=1.56~4.48,I^(2)=0%,P=0.0003)。SBRT组与RFA组间晚期严重不良反应发生率差异无统计学意义(OR=1.01,95%CI=0.59~1.73,I^(2)=30%,P=0.97)。结论SBRT与RFA相比虽未表现出生存获益上的优势,但在HCC局部控制方面表现出较优的效果,尤其是对肿瘤直径>2 cm的患者。展开更多
This study was to evaluate effect of ^(125)I brachytherapy combined with chemotherapy on advanced non-small cell lung cancer(NSCLC). Patients with NSCLC in stages III to IV were divided into two groups: Group A(n = 27...This study was to evaluate effect of ^(125)I brachytherapy combined with chemotherapy on advanced non-small cell lung cancer(NSCLC). Patients with NSCLC in stages III to IV were divided into two groups: Group A(n = 27) received ^(125)I brachytherapy combined with gemcitabine and cisplatin(GP) chemotherapy, and Group B(n = 27) received GP chemotherapy only. The results showed that the overall response rate and median progression-free survival time were 78% and 11.5 months in Group A, 41% and 8 months in Group B, respectively(P < 0.05). For Group A, the 1- and 2-years survival rates were 67% and 37%, respectively,with the median survival time of 16 months, whereas the corresponding data of Group B were 48%, 22% and 11.5 months(P > 0.05). The interventional complications in Group A included 5 patients with postoperative pneumothorax and 4 patients with hemoptysis. No patients had radiation pneumonia, radiation esophagitis or esophagotracheal fistula. Chemotherapy treatment-related toxicities were not significantly different between the two groups. The relief of tumor-associated symptoms including cough, hemoptysis, chest pain, and short breath was found in both groups, without statistical difference in remission rates between Groups A and B(P > 0.05).In conclusion, ^(125)I brachytherapy combined with chemotherapy proved to be safe and effective for treating advanced NSCLC with few complications. It improves local control rate and prolongs the progression-free survival time.展开更多
基金Supported by the research fund of Science and Technology Department of Jilin Province(No.201115088)
文摘This study was to evaluate effect of ^(125)I brachytherapy combined with chemotherapy on advanced non-small cell lung cancer(NSCLC). Patients with NSCLC in stages III to IV were divided into two groups: Group A(n = 27) received ^(125)I brachytherapy combined with gemcitabine and cisplatin(GP) chemotherapy, and Group B(n = 27) received GP chemotherapy only. The results showed that the overall response rate and median progression-free survival time were 78% and 11.5 months in Group A, 41% and 8 months in Group B, respectively(P < 0.05). For Group A, the 1- and 2-years survival rates were 67% and 37%, respectively,with the median survival time of 16 months, whereas the corresponding data of Group B were 48%, 22% and 11.5 months(P > 0.05). The interventional complications in Group A included 5 patients with postoperative pneumothorax and 4 patients with hemoptysis. No patients had radiation pneumonia, radiation esophagitis or esophagotracheal fistula. Chemotherapy treatment-related toxicities were not significantly different between the two groups. The relief of tumor-associated symptoms including cough, hemoptysis, chest pain, and short breath was found in both groups, without statistical difference in remission rates between Groups A and B(P > 0.05).In conclusion, ^(125)I brachytherapy combined with chemotherapy proved to be safe and effective for treating advanced NSCLC with few complications. It improves local control rate and prolongs the progression-free survival time.
